#Japan #Gilead Sciences #Chiyoda #Bictegravir #Lenacapavir

Gilead Submits Application for HIV-1 Treatment in Japan

Gilead Sciences, a leading biopharmaceutical company headquartered in Chiyoda, Tokyo, has recently announced the submission of a manufacturing and marketing approval application for the combination drug of Bictegravir and Lenacapavir (BIC/LEN) in Japan. This application marks a significant advancement in the treatment options available for HIV-1 infected patients.

New Hope for HIV Patients

The proposed BIC/LEN regimen is a once-daily single-tablet treatment designed to offer a new alternative for individuals who have achieved virological suppression but have previously struggled with existing antiviral treatment regimens. Gilead aims to provide reliable treatment solutions that are not only effective but also manageable for patients dealing with HIV.

The innovative combination features Bictegravir, an integrase strand transfer inhibitor (INSTI) recognized for its high barrier to resistance, and Lenacapavir, a first-in-class capsid inhibitor that does not exhibit cross-resistance with existing classes of HIV medications. This unique formulation showcases Gilead's commitment to scientific innovation and improving treatment outcomes for patients.

The Clinical Trials Behind the Approval

The application is grounded in the encouraging results from two international phase II/III clinical trials, ARTISTRY-1 and ARTISTRY-2, both focusing on adult HIV-positive participants who demonstrated virological suppression while on multi-tablet regimens or international guideline-recommended treatments.

In these trials, BIC/LEN proved noninferior to existing therapies regarding the maintenance of virological suppression. The overall tolerance of the drug combination was good, and no significant safety concerns emerged during the studies. This research highlights Gilead's thorough approach to developing therapies that ensure both efficacy and safety.

A Commitment to Ending the HIV Epidemic

Gilead's President, Andrew Hexter, stated, "For over 35 years, Gilead has contributed to the advancement of HIV treatment through continuous scientific innovation, aiming to end the global HIV epidemic. This application exemplifies our steadfast commitment to support people living with HIV in achieving long-term, stable treatment outcomes while reducing the risk of HIV transmission in society."

As a cornerstone in the HIV treatment landscape, Gilead Sciences has relentlessly pursued the development of therapies that revolutionize the way HIV is managed. The BIC/LEN combination is anticipated to expand the treatment options available, assisting in the global effort to conclude the HIV epidemic by 2030.

About Gilead Sciences

Gilead Sciences, founded more than 35 years ago, is dedicated to achieving a healthier world through innovative medical solutions. Headquartered in Foster City, California, the company operates in more than 35 countries and focuses on addressing critical illnesses such as HIV, viral hepatitis, COVID-19, cancer, and inflammatory diseases.

With a mission to empower patients and enhance healthcare access, Gilead is continuously working to address the evolving needs of individuals living with HIV. Through collaborations, partnerships, and charitable contributions, Gilead actively promotes educational development and strives to break down barriers to treatment, fostering a world where the HIV epidemic can be brought to an end.